Effect of PSA decreasing of a pollen extract(Cernilton) for patients with prostate biopsy: multicenter study

Effect of PSA decreasing of a pollen extract(Cernilton) for patients with prostate biopsy: multicenter study - Effect of PSA decreasing of a pollen extract(Cernilton)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017593

Enrollment

120

Registered

2015-05-15

Start date

2014-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

suspected prostate cancer

Interventions

prostate biopsy

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: patients with first episode for prostate biopsy patients who PSA lebel is from 4 to 20 ng/ml patients who have no induration on digital rectal examination

Exclusion criteria

Exclusion criteria: patients who using antimicrobial agent with in 3 months patients who using a pollen extract(Cernilton) within 1 year patients who decide not to join this study

Design outcomes

Primary

Measure	Time frame
PSA decreasing rate cancer detection rate	—

Countries

Japan

Contacts

Public ContactYoshikazu Togo

Hyogo College of Medicine Department of Urology

ytogo@hyo-med.ac.jp0798-45-6366

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026